1. Systemic complications of Aicardi Goutières syndrome using real-world data.
- Author
-
Peixoto de Barcelos I, Jan AK, Modesti N, Woidill S, Gavazzi F, Isaacs D, D'Aiello R, Sevagamoorthy A, Charlton L, Pizzino A, Schmidt J, van Haren K, Keller S, Eichler F, Emrick LT, Fraser JL, Shults J, Vanderver A, and Adang LA
- Subjects
- Humans, Female, Male, Child, Preschool, Infant, Child, Phosphoproteins genetics, Exodeoxyribonucleases genetics, Retrospective Studies, Adolescent, Ribonuclease H genetics, SAM Domain and HD Domain-Containing Protein 1 genetics, Genotype, Severity of Illness Index, Mutation, Interferon-Induced Helicase, IFIH1 genetics, Nervous System Malformations genetics, Nervous System Malformations complications, Nervous System Malformations epidemiology, Autoimmune Diseases of the Nervous System genetics, Autoimmune Diseases of the Nervous System complications
- Abstract
Objective: Aicardi Goutières Syndrome (AGS) is a rare genetic interferonopathy associated with diverse multisystemic complications. A critical gap exists in our understanding of its longitudinal, systemic disease burden, complicated by delayed diagnosis. To address this need, real-world data extracted from existing medical records were used to characterize the longitudinal disease burden., Methods: All subjects (n = 167) with genetically confirmed AGS enrolled in the Myelin Disorders Biorepository Project (MDBP) were included. As available in medical records, information was collected on subject demographics, age of onset, and disease complications. Information from published cases of AGS (2007-2022; n = 129) with individual-level data was also collected. Neurologic severity at the last available encounter was determined by retrospectively assigning the AGS Severity Scale [severe (0-3), moderate (4-8), and mild (9-11)]., Results: The genotype frequency in the natural history cohort was TREX1 (n = 26, 15.6 %), RNASEH2B (n = 50, 29.9 %), RNASEH2C (n = 3, 1.8 %), RNASEH2A (n = 7, 4.2 %), SAMHD1 (n = 25, 15.0 %), ADAR (n = 34, 20.4 %), IFIH1 (n = 19, 11.4 %), and RNU7-1 (n = 3, 1.8 %). The median age of systemic onset was 0.15 years [IQR = 0.67 years; median range by genotype: 0 (TREX1) - 0.62 (ADAR) years], while the median neurological onset was 0.33 years [IQR = 0.82 years; median range by genotype: 0.08 (TREX1) - 0.90 (ADAR) year]. The most common early systemic complications were gastrointestinal, including dysphagia or feeding intolerance (n = 124) and liver abnormalities (n = 67). Among postnatal complications, thrombocytopenia appeared earliest (n = 29, median 0.06 years). Tone abnormalities (axial hypotonia: n = 145, 86.8 %; dystonia: n = 123, 73.7 %), irritability (n = 115, 68.9 %), and gross motor delay (n = 112, 7.1 %) emerged as the most prevalent neurological symptoms. Previously published case reports demonstrated similar patterns. The median AGS score for the entire cohort was 4 (IQR = 7). The most severe neurologic phenotype occurred in TREX1-related AGS (n = 19, median AGS severity score 2, IQR = 2). Time to feeding tube placement, chilblains, early gross motor delay, early cognitive delay, and motor regression were significantly associated with genotype (Fleming-Harrington log-rank: p = 0.0002, p < 0.0001, p = 0.0038, p < 0.0001, p = 0.0001, respectively). Microcephaly, feeding tube placement, and seizures were associated with lower AGS scores (All: Wilcoxon rank sum test, p < 0.0001). Among the qualifying case reports (n = 129), tone abnormalities were the most prevalent disease feature, with spastic quadriplegia reported in 37 of 96 cases (38.5 %) and dystonia in 30 of 96 cases (31.2 %)., Conclusions: AGS is a heterogeneous disease with multi-organ system dysfunction that compounds throughout the clinical course, resulting in profound neurological and extra-neurological disease impact. Systemic symptoms precede neurologic disease features in most cases. Disease onset before the age of one year, microcephaly, feeding tube placement, and seizures were associated with worse neurological outcomes. This work will inform evidence-based clinical monitoring guidelines and clinical trial design., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that influence the work reported in this paper. AV receives research support from Gilead Sciences Inc., Homology Medicines, Eli Lilly and Company, Shire/Takeda, Ionis, Biogen, and Ilumina Inc. She is a consultant to Orchard Pharmaceutical. She has provided unpaid scientific advisory services to Illumina, Shire/Takeda, Ionis, and Biogen, in addition to the research support she receives. AV receives grants and in-kind support for research from Eli Lilly, Gilead, Takeda, Illumina, Biogen, Boehringer Ingelhiem, Sanofi, Sana, Myrtelle, Affinia, Homology, Ionis, Passage Bio, and Orchard Therapeutics. AV serves on the scientific advisory boards of the MLD Foundation, European Leukodystrophy Association, and the United Leukodystrophy Foundation and in an unpaid capacity for Takeda, Ionis, Biogen, and Illumina. LAA is a consultant for Takeda, Biogen, and Orchard Therapeutics. LE serves on the Ionis Pharmaceuticals Board of Directors., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF